AdAlta Limited is developing clinical imaging of the cell surface receptor CXCR4 in idiopathic pulmonary fibrosis (IPF) patients. IPF is a progressive lung disease consisting of recurring inflammation and damage that causes the lung to stiffen, making it hard to breathe.
AdAlta has identified a therapeutic protein called AD-214, that incorporates its i-body technology and demonstrates potent anti-fibrotic properties via a novel mechanism of action. AD-214 is being developed for the treatment of fibrotic diseases including a debilitating lung fibrosis condition called Idiopathic Pulmonary Fibrosis (IPF).
This disease affects approximately 10,000 Australians and more than 500,000 people worldwide with the median length of survival from diagnosis being only 3 to 5 years. Currently available treatments have broad or vague mechanisms of action, multiple side effects and merely slow disease progression.
AD-214 binds with great specificity to its target, the G-protein coupled receptor CXCR4, is effective in pre-clinical studies of fibrosis and could be a first in class/best in class treatment for IPF. This project will seek to label or tag AD-214 so that it can be non-invasively imaged during its evaluation in IPF patients, confirming distribution, binding and duration of engagement to the target, CXCR4, in the lung.
Visit AdAlta for more information.
BTB Round: First
LinkedIn: AdAlta Ltd
Project Partners: Alfred Hospital, Monash University, Olivia Newton-John Cancer Research Institute/Austin Health and University of Melbourne
Contact: AdAlta Enquiries